- In August 2024, Altogen Labs, a prominent preclinical contract research organization (CRO), announced the successful validation of a comprehensive set of 10 lung cancer xenograft models. These models are essential for evaluating the in vivo efficacy of novel therapeutics aimed at treating lung cancer, thereby advancing the understanding, diagnosis, and treatment of primary lung carcinoma. This development underscores the growing role of patient-derived xenograft (PDX) models in accelerating cancer research and therapeutic innovation, contributing to the expansion of the global PDX market, particularly in oncology drug development
- In May 2024, BioAtla, Inc., a clinical-stage biotechnology company, announced receiving FDA authorization for its innovative antibody-drug conjugate (ADC) BA3361, designed to target multiple tumor types. The company demonstrated the superior efficacy of BA3361 in both cell line-derived xenograft models and patient-derived xenograft (PDX) models, including pancreatic cancer, showcasing complete tumor regression and reduced toxicity owing to CAB selectivity. This advancement highlights the growing importance of PDX models in the development of targeted cancer therapies, further driving the demand for PDX models within the global oncology research and therapeutic landscape
- In March 2024, Crown Bioscience, a leading global contract research organization (CRO), announced its plans to present groundbreaking research at the AACR 2024 meeting, featuring data derived from its Patient-Derived Xenograft (PDX) models. These PDX models are integral to advancing preclinical oncology research, facilitating the development of more targeted and personalized cancer therapies. This development underscores the increasing reliance on PDX models in oncology research, fueling the growth and adoption of PDX models in the global biotechnology and pharmaceutical sectors
- In December 2022, Crown Bioscience, Inc., a subsidiary of JSR Life Sciences, entered into a global licensing agreement with ERS Genomics Limited, granting the company comprehensive access to ERS's CRISPR/Cas9 patent portfolio. This agreement allows Crown Bioscience to leverage CRISPR/Cas9 technology for genetic editing on a global scale. This development highlights the growing significance of advanced genetic tools in enhancing the precision and effectiveness of patient-derived xenograft (PDX) models, which are crucial in the development of personalized cancer therapies and further propels the global PDX market's expansion
- In July 2022, GemPharmatech formed a strategic licensing partnership with Charles River Laboratories, Inc., granting the company exclusive distribution rights for GemPharmatech's advanced NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America. The availability of these specialized models further contributes to the growing demand for PDX-based studies, advancing the development of personalized cancer therapies and supporting the global PDX market
